Advanced RCC benefits from multimodal approach

Article

Patients with metastatic renal cell cancer historically have had a poorprognosis, and attempts with hormonal therapy and chemotherapy have haddisappointing results. In this exclusive Urology Times interview, W. MarstonLinehan, MD, discusses new treatment strategies for renal cell carcinoma,including multimodality therapy with surgery and systemic therapy, and adoptiveimmunotherapy. Dr. Linehan is chief of urologic surgery at the NationalCancer Institute, Bethesda, MD. UT Editorial Consultant Andrew C. Novick,MD, chairman of the Cleveland Clinic Urological Institute, conducted theinterview.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Sad surgeon sitting on floor in corridor | Image Credit: © WavebreakMediaMicro - stock.adobe.com
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer
Man talking with doctor | © DragonImages - stock.adobe.com
Kevin Turner MA DM FRCS(Urol), answers a question during a Zoom video interview
A panel of 3 experts on overactive bladder
Related Content
© 2024 MJH Life Sciences

All rights reserved.